Lawrence J. Brandt, MD; Erik Dubberke, MD; Daniel E. Freedberg, MD, MS; Dale N. Gerding, MD; Yoav Golan, MD, MS; and Peter L. Salgo, MD, introduce bezlotoxumab, an additional treatment option that is in the pipeline for Clostridium difficile; explore how it works; and suggest which types of patients may be most appropriate to receive this treatment.
